Publications
CIBMTR Publication List
Since 1972, using CIBMTR data and statistical resources has resulted in more than 1,800 publications.
CIBMTR also makes its publication analysis datasets freely available to the public for secondary analysis while safeguarding participants' privacy and protecting confidential and proprietary data.
Browse Publications
2025 | Haematologica
CD19 directed CAR T therapy for intravascular large B-cell lymphoma.
Authors:
Patel J, Gopal A, Cherniawsky H, Ram R, Kamble R, Hamadani M
2025 | American Journal of Hematology
CD19 CAR T-cell therapy for primary mediastinal large B-cell lymphoma: a CIBMTR analysis.
Authors:
Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikran K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF
2025 | American Journal of Hematology
CD19 directed CAR T therapy for transformed follicular lymphoma: A CIBMTR Analysis.
Authors:
Thiruvengadam SK, Ahn KW, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera AF
2025 | Transplantation and Cellular Therapy
Chimeric antigen receptor T-cell therapy for richter transformation: A CIBMTR analysis.
Authors:
Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M
2025 | British Journal of Haematology
Chimeric antigen receptor T-cell therapy for high grade B-cell lymphoma NOS.
Authors:
Hossain NM, Ahn KW, Patel J, Lian Q, Bilal Abid M, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF
Authors:
Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, Finel H, Kulagin A, Glass B, Corradini P, Herrera AF, Blaise D, Kharfan-Dabaja MA, Halahleh K, Ahmed S, Martinez C, Giebel S, Montoto S, Jones RJ, Ahmed N, Lynch RC, de Lima MJ, Shadman M, Sauter CS, Ahn KW, Hamadani M, Bazarbachi A, Sureda A
2025 | American Journal of Hematology
Autologous transplant or CAR-T as consolidation options in MYC rearranged large B-cell lymphoma patients in remission after salvage treatments.
Authors:
Furqan F, Ahn KW, Kaur M, Patel J, Ansell S, Awan FT, Baird J, Bezerra E, Farooq U, Fung H, Khurana A, Lekakis L, Lutfi F, McCarty J, Mukherjee D, Nath R, Romancik J, Schuster SJ, Smith M, Winter A, Turtle C, Sauter C, Shadman M, Herrera A, Hamadani M
2024 | Haematologica
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy.
Authors:
Mercadal S, Ahn KW, Allbee-Johnson M, Ganguly S, Ramakrishnan Geethakumari P, Hong S, Malone A, Murthy H, Pawarode A, Sica AR, Solh M, Ustun C, Shadman M, Sauter CS, Hamadani M, Herrera AF, Lee CJ
2024 | Blood Advances
CD19-directed CART therapy for T cell/histiocyte rich large B-cell lymphoma.
Authors:
Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter L, Sauter CS, Hamadani M, Herrera AF, Shouval R, Shadman M
2024 | Blood Cancer Journal
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.
Authors:
Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M
2024 | British Journal of Haematology
Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
Authors:
Epperla N, Hashmi H, Ahn KW, Chen AI, Wirk B, Kanakry JA, Lekakis L, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed S
Authors:
Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A
2022 | British Journal of Haematology
Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Authors:
Furqan F, Ahn KW, Chen Y, Kaur M, Abutalib SA, Ahmed N, Ahmed S, Kharfan-Dabaja MA, Friedberg J, Gregory T, Hill L, Sterling C, Barta SK, Shadman M, Perales MA, Zain J, Herrera AF, Sauter C, Hamadani M
2022 | Transplantation and Cellular Therapy
Outcomes of autologous hematopoietic cell transplantation in older patients with diffuse large B-cell lymphoma.
Authors:
Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M
2022 | Haematologica
Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: Evidence of durable benefit.
Authors:
Mei M, Hamadani M, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF
2022 | British Journal of Haematology
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
Authors:
Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M
Authors:
Iqbal M, Savani BN, Hamadani M
2021 | Hematology / the Education Program of t...
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
Authors:
Epperla N, Hamadani M
2021 | Blood Advances
Outcome of allogeneic transplantation for mature T-cell lymphomas: Impact of donor source and disease characteristics.
Authors:
Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P
2021 | British Journal of Haematology
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
Authors:
Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM